Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways.

Journal of neurochemistry | 2008

GTP binding regulatory protein (G protein)-coupled receptors can activate MAPK pathways via G protein-dependent and -independent mechanisms. However, the physiological outcomes correlated with the cellular signaling events are not as well characterized. In this study, we examine the involvement of G protein and beta-arrestin 2 pathways in kappa opioid receptor-induced, extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated proliferation of both immortalized and primary astrocyte cultures. As different agonists induce different cellular signaling pathways, we tested the prototypic kappa agonist, U69593 as well as the structurally distinct, non-nitrogenous agonist, C(2)-methoxymethyl salvinorin B (MOM-Sal-B). In immortalized astrocytes, U69593, activated ERK1/2 by a rapid (min) initial stimulation that was sustained over 2 h and increased proliferation. Sequestration of activated Gbetagamma subunits attenuated U69593 stimulation of ERK1/2 and suppressed proliferation in these cells. Furthermore, small interfering RNA silencing of beta-arrestin 2 diminished sustained ERK activation induced by U69593. In contrast, MOM-Sal-B induced only the early phase of ERK1/2 phosphorylation and did not affect proliferation of immortalized astrocytes. In primary astrocytes, U69593 produced the same effects as seen in immortalized astrocytes. MOM-Sal-B elicited sustained ERK1/2 activation which was correlated with increased primary astrocyte proliferation. Proliferative actions of both agonists were abolished by either inhibition of ERK1/2, Gbetagamma subunits or beta-arrestin 2, suggesting that both G protein-dependent and -independent ERK pathways are required for this outcome.

Pubmed ID: 19014370 RIS Download

Research resources used in this publication

None found

Associated grants

  • Agency: NIDA NIH HHS, United States
    Id: R01 DA018860-05
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA005412-17
  • Agency: NIDA NIH HHS, United States
    Id: DA-05412
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA005412
  • Agency: NIDA NIH HHS, United States
    Id: R01 DA018860
  • Agency: NIDA NIH HHS, United States
    Id: K01 DA014600-06
  • Agency: NIDA NIH HHS, United States
    Id: DA-18860
  • Agency: NIDA NIH HHS, United States
    Id: K01 DA014600

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ImmunoStar (tool)

RRID:SCR_013473

An Antibody supplier

View all literature mentions

Neuromics (tool)

RRID:SCR_013518

An Antibody supplier

View all literature mentions

List Biological Laboratories (tool)

RRID:SCR_014324

Organization which manufactures bacteria for research and clinical investigations. List Biological Laboratories cultivates native and recombinant microorganisms and purifies, formulates, and lyopholizes enzyme products, virulence factors, and microbial cell wall components. Products include antibodies, microbial toxins, peptides, and virulence factors. Services include live biotherapeutics for clinical trials, contracting research capabilities, GMP regulatory support, lyopholization services and support, and toxin compliance.

View all literature mentions

List Biological Laboratories (tool)

RRID:SCR_013406

Organization which manufactures bacteria for research and clinical investigations. List Biological Laboratories cultivates native and recombinant microorganisms and purifies, formulates, and lyopholizes enzyme products, virulence factors, and microbial cell wall components. Products include antibodies, microbial toxins, peptides, and virulence factors. Services include live biotherapeutics for clinical trials, contracting research capabilities, GMP regulatory support, lyopholization services and support, and toxin compliance.

View all literature mentions

GFAP (Glial Fibrillary Acid Protein) Antibody (antibody)

RRID:AB_572240

This polyclonal targets Glial Fibrillary Acid Protein

View all literature mentions